Héctor García-Calderó

Mr. Héctor García-Calderó

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMarcos Pasarín
Marcos Pasarín
VMVincenzo La Mura
Vincenzo La Mura
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho
HGHéctor García-Calderó
Héctor García-Calderó
ARAina Rodríguez-Vilarrupla
Aina Rodríguez-Vilarrupla
JAJuan G Abraldes
Juan G Abraldes
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Most morbidity associated with the metabolic syndrome is related to vascular complications, in which endothelial dysfunction is a major pathogenic factor. However, whether NAFLD is associated with endothelial dysfunction within the hepatic vasculature is unknown. The aims of this study were to explore, in a model of diet-induced overweight that expresses most features of the metabolic syndrome, whether early NAFLD is associated with liver endothelial dysfunction. Wistar Kyoto rats were fed a cafeteria diet (CafD; 65% of fat, mostly saturated) or a control diet (CD) for 1 month. CafD rats developed features of the metabolic syndrome (overweight, arterial hypertension, hypertryglyceridemia, hyperglucemia and insulin resistance) and liver steatosis without inflammation or fibrosis. CafD rats had a significantly higher in vivo hepatic vascular resistance than CD. In liver perfusion livers from CafD rats had an increased portal perfusion pressure and decreased endothelium-dependent vasodilation. This was associated with a decreased Akt-dependent eNOS phosphorylation and NOS activity. In summary, we demonstrate in a rat model of the metabolic syndrome that shows features of NAFLD, that liver endothelial dysfunction occurs before the development of fibrosis or inflammation.

1 June 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
JAJuan G. Abraldes
Juan G. Abraldes
ARAina Rodríguez-Vilarrupla
Aina Rodríguez-Vilarrupla
MGMariona Graupera
Mariona Graupera
CZCarmen Zafra
Carmen Zafra
HGHéctor García-Calderó
Héctor García-Calderó
JBJaime Bosch
Jaime Bosch

10 December 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho
BLBàrbara Laviña
Bàrbara Laviña
ARAina Rodríguez‐Vilarrupla
Aina Rodríguez‐Vilarrupla
HGHéctor García-Calderó
Héctor García-Calderó
MFMercedes Fernández
Mercedes Fernández
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
In cirrhotic livers, decreased nitric oxide (NO) bioavailability is a major factor increasing intrahepatic vascular tone. In several vascular disorders, an increase in superoxide (O2−) has been shown to contribute to reduced NO bioavailability through its reaction with NO to form peroxynitrite. This study was aimed to test the hypothesis that, in cirrhotic livers, increased O2−, by reacting with NO, reduces NO bioavailability. In control and cirrhotic rat livers, NO bioavailability was evaluated by the measurement of cyclic guanosine monophosphate in liver tissue and by 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM-DA) fluorescence in isolated sinusoidal endothelial cells (SEC); the O2− content was determined by dihydroethidium staining in fresh liver sections. In addition, the role of endothelial nitric oxide synthase (eNOS), xanthine oxidase (XO), and cyclooxygenase (COX) as possible sources of O2− and the role of superoxide dismutase (SOD) enzymatic activity as an O2− scavenger were determined in liver homogenates. Protein-nitrotyrosination, a marker of the NO-O2− reaction, was evaluated in liver homogenates. Furthermore, in control SEC and bovine aortic endothelial cells, NO modulation by O2− was evaluated. Cirrhotic livers exhibited increased O2− levels. This was due, at least in part, to increased production by COX and XO but not eNOS and to reduced scavenging by SOD. Increased O2− was associated with a significant reduction in NO bioavailability and increased nitrotyrosinated proteins. In endothelial cells, an inverse relationship between O2− levels and NO bioavailability was observed. Conclusion: Our data show that oxidative stress may contribute to reduced NO bioavailability in cirrhotic livers, supporting the evaluation of O2− reduction as a potential mechanism to restore NO content. (HEPATOLOGY 2008.)

26 November 2010 in Gut
Verified
Journal Article
Closed access
PDF file
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho
LRLucia Russo
Lucia Russo
HGHéctor García-Calderó
Héctor García-Calderó
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
GGGuillermo García-Cardeña
Guillermo García-Cardeña
JBJaime Bosch
Jaime Bosch
Objective The transcription factor Kruppel-like factor 2 (KLF2) modulates the expression of multiple endothelial vasoprotective genes. In the absence of KLF2, the endothelial phenotype becomes dysfunctional. To date, blood-derived shear stress is the main physiological stimulus identified to trigger and sustain endothelial KLF2 expression. Portal hypertension is a common complication of cirrhosis. Sinusoidal distortion and endothelial dysfunction play a significant role in its pathogenesis. This study aimed to assess whether abnormal intrahepatic haemodynamics in cirrhosis could modify KLF2 expression and consequently its downstream transcriptional programmes. Design Rats received carbon tetrachloride or vehicle for two (acute injury), six (early cirrhosis) and twelve weeks (advanced cirrhosis). Systemic and hepatic haemodynamic parameters were measured in vivo. Hepatic expression of KLF2 and its vasoprotective targets were determined. Additionally, KLF2 expression was determined in liver sections, in freshly-isolated hepatic endothelial cells, and in livers from simvastatin-treated cirrhotic animals. Results Cirrhotic livers have increased endothelial KLF2 expression compared with controls. KLF2 elevation, observed at six weeks of cirrhosis induction, was accompanied by a parallel increase in portal pressure and an increase in the expression of its target genes eNOS, thrombomodulin and CNP. Simvastatin administration further increased hepatic KLF2 and target genes expression. Conclusions This study shows an increase in the expression of the vasoprotective transcription factor KLF2 in the cirrhotic liver, accompanied by an activation of its downstream transcriptional programmes. These data suggest that the marked increase in KLF2 expression may represent an endothelial compensatory mechanism to improve the ongoing vascular dysfunction in the cirrhotic liver.

1 August 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho
BLBàrbara Laviña
Bàrbara Laviña
ARAina Rodríguez-Vilarrupla
Aina Rodríguez-Vilarrupla
HGHéctor García-Calderó
Héctor García-Calderó
JBJaime Bosch
Jaime Bosch
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

1 November 2018 in Gastroenterology
Verified
Journal Article
Open access
DTDINESH MANI TRIPATHI
DINESH MANI TRIPATHI
MVMarina Vilaseca
Marina Vilaseca
ELErica Lafoz
Erica Lafoz
HGHéctor García-Calderó
Héctor García-Calderó
GHGabriela Viegas Haute
Gabriela Viegas Haute
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho
Cirrhosis and its clinical consequences can be aggravated by bacterial infections, ultimately leading to the development of acute on chronic liver failure (ACLF), characterized by acute decompensation, organ failure, and high mortality within 28 days. Little is known about cellular and molecular mechanisms of ACLF in patients with cirrhosis, so no therapeutic options are available. We developed a sepsis-associated preclinical model of ACLF to facilitate studies of pathogenesis and evaluate the protective effects of simvastatin. Male Wistar rats inhaled CCl4 until they developed cirrhosis (at 10 weeks) or cirrhosis with ascites (at 15-16 weeks). Male Sprague-Dawley rats received bile-duct ligation for 28 days or intraperitoneal thioacetamide for 10 weeks to induce cirrhosis. After induction of cirrhosis, some rats received a single injection of lipopolysaccharide (LPS) to induce ACLF; some were given simvastatin or vehicle (control) 4 hours or 24 hours before induction of ACLF. We collected data on changes in hepatic and systemic hemodynamics, hepatic microvascular phenotype and function, and survival times. Liver tissues and plasma were collected and analyzed by immunoblots, quantitative polymerase chain reaction, immuno(fluoro)histochemistry and immunoassays. Administration of LPS aggravated portal hypertension in rats with cirrhosis by increasing the severity of intrahepatic microvascular dysfunction, exacerbating hepatic inflammation, increasing oxidative stress, and recruiting hepatic stellate cells and neutrophils. Rats with cirrhosis given LPS had significantly shorter survival times than rats with cirrhosis given the control. Simvastatin prevented most of ACLF-derived complications and increased survival times. Simvastatin appeared to increase hepatic sinusoidal function and reduce portal hypertension and markers of inflammation and oxidation. The drug significantly reduced levels of transaminases, total bilirubin, and ammonia, as well as LPS-mediated activation of hepatic stellate cells in liver tissues of rats with cirrhosis. In studies of rats with cirrhosis, we found administration of LPS to promote development of ACLF, aggravating the complications of chronic liver disease and decreasing survival times. Simvastatin reduced LPS-induced inflammation and liver damage in rats with ACLF, supporting its use in treatment of patients with advanced chronic liver disease.